C. Diff clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
The purpose of this research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults > or equal to 18 years of age with a primary episode or first recurrence of CDI. The study will investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy endpoints as secondary objectives.
Orange, California and other locations
Our lead scientists for C. Diff research studies include Alpesh Amin, MD.